Pioneering diagnostics
E.g., 21/11/2019
E.g., 21/11/2019
PreviousNext

bioMérieux receives FDA clearance for BPA and BPN culture bottles used with BACT/ALERT® VIRTUO® for quality control testing of platelets

19 December, 2018

 
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-...

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY®...

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 November, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018.
 
Founded in...

Business review for the nine months ended September 30, 2018

18 October, 2018

  • Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
  • Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
    • €1,749 million in sales
    • Up 4.5% as reported
    ...

bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance

25 September, 2018

Marcy l’Étoile (France) – Sept. 25, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for...

First-Half 2018 Results

05 September, 2018

  • Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales
    • Up 3.1% as reported
  • Contributive operating income before non-...

Second-Quarter 2018 Business Review

18 July, 2018

  • Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales 
    • Up 3.1% as reported
  • ...

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations

12 June, 2018

The biomarkers in the NEPHROCHECK® test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury (...

bioMérieux launches ENDOZYME® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control

31 May, 2018

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new...

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery

02 May, 2018

Marcy l’Étoile (France) and San Diego (California) - May 2nd, 2018 – The biomarkers in the...

PreviousNext